"Your Partner of Choice and your gate to the Middle East and North Africa (MENA) Pharmaceutical World"


Genpharm Services is a financially sound privately owned company based in the Dubai Science Park (DSP), U.A.E. We provide fast-track Market Access to specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA) region. We focus on innovative and orphan drugs in areas of unmet medical needs, rare genetic disorders and autoimmune diseases.

Pharmaceutical Strategic Advice

"We also provide Management Consultancy for companies aiming at expanding directly into this dynamic region of high growth. We advise on strategies, structures and operating business models in line with the respective company priorities and portfolio. "

The Healthcare and pharmaceutical expert panel during the Dubai Investment Forum: "These are the global pharmaceutical trends that will no doubt leave a major impact on the industry not only globally but regionally as well”, Karim Smaira

Genpharm’s CEO, Karim Smaira shared his insights on the global trends in the pharmaceutical industry that are impacting the regional Middl East Pharmaceutical sector. "Although the Middle East represents less than 3% of global pharmaceutical sales, the region posts growth rates that are higher than the global average growth. This provides opportunities for investors.

Is this the Era of Biosimilars?

According to reports from IMS Health and Deloitte, biologics are already a $150-billion-plus industry globally and are expected to double by 2020, accounting for more than 27% of the pharmaceutical market. Analysts also expect the worldwide biosimilars market to grow, reaching approximately $35 billion by 2020. The Middle East and Africa Biosimilars Market was worth $0.37 billion in 2016 and estimated to be growing at a CAGR of 32%, to reach $1.63 billion by 2021, according to a report from Market Data Forecast. The MENA region can be considered as influential and attractive pharmaceutical markets among other emerging markets.

His Excellency Sheikh Nahyan bin Mubarak Al Nahyan honoring Genpharm for their role in raising awareness on Rare Diseases and for their contribution on Rare Disease Day

His Excellency Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Culture and the development of knowledge, president of the UAE Genetic Diseases Association, honored several specialized experts in rare diseases, as part of the annual Emirates International Award for reducing genetic diseases "rare disease category" in its third session.

Aspire Educational Series: OlivoPontoCerebellar Atrophy (OPCA)- Part 22

Olivopontocerebellar atrophy can be passed down through families (inherited form), or it may affect people without a known family history (sporadic form). Researchers have identified certain genes that are involved in the inherited form of this condition. In this disease brain cell of the particular part of brain namely the pons, cerebellum and inferior olive begin to degenerate and die.

Genpharm Awarded for the Second Consecutive Year, the Best MENA Pharmaceutical Company for 2017

GENPHARM Services - Your Gateway to the MENA Pharmaceutical Market

We are a specialty pharmaceutical marketing and consulting company, providing our strategic partners with fast and sustainable market access into the MENA (Middle East & North Africa) region, including business development, in-licensing and more. We operate through evidence-based medicine and the highest ethical standards. Our expertise is based on an in-depth knowledge of the pharmaceutical market and the local business culture. Furthermore, our vast experience and the trusted network of partners allow us to deliver market opportunities for specialty, rare disease, biotech, and innovative healthcare organizations.

The MENA region has been experiencing fast economic and sustainable GDP growth. This positive outlook is driven by several factors providing pharmaceutical companies with untapped regional opportunities...
The healthcare sector in the MENA region has been experiencing sustainable double digit growth. Driven by unmet medical needs and increased medical public awareness, governments have been heavily investing in both infrastructure and access
We operate through a holistic market approach. We manage all relevant stakeholders for our partners, including Physicians, Patient groups, distributors and payers. Our expertise include KOL management, advocacy and CME programs..
Genpharm Services is managed by highly experienced Pharma executives. The operations are led by staff with a strong track record in senior leadership roles in multinational pharmaceutical organizations...